6. (Amended) A pharmaceutical composition for use in treating neuropathic pain, which is administered by a systemic method of administration and which comprises a compound having mGluR1 antagonistic activity, wherein the compound having mGluR1 antagonism is a compound selected from 6-amino-N-cyclohexyl-N,3-dimethylthiazolo[3,2-a]benzoimidazole-2-carboxamide dihydrochloride and (+)-(1*R*,2*S*)-6-amino-N-methyl-N-(2-methylcyclohexyl)thiazolo[3,2-a]benzoimidazole-2-carboxamide dihydrochloride.

Please add the following new claims:

7. (New) A method for improving neuropathic pain which comprises systemically administering to a subject a compound having mG1uR1 antagonistic activity and having no activity on Group II and Group III of metabotropic glutamate in an amount effective for improving neuropathic pain.

8. (New) The method according to claim 7, wherein the neuropathic pain is induced by diabetes or compression of nerves.

9. (New) The method according to claim 8, wherein the neuropathic pain is induced by diabetes.

10. (New) The method according to claim 7, wherein the systemic administration method is oral administration.

11. (New) The method according to claim 7, wherein the compound having mGluR1 antagonistic activity and having no activity on Group II and Group III of metabotropic glutamate is a compound selected from 6-amino-N-cyclohexyl-N,3-dimethylthiazolo[3,2-

a]benzoimidazole-2-carboxamide dihydrochloride and (+)-(1*R*,2*S*)-6-amino-N-methyl-N-(2-methylcyclohexyl)thiazolo[3,2-a]benzoimidazole-2-carboxamide dihydrochloride.